DUBLIN--(BUSINESS WIRE)--The "Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. The market for PIM ...
FD-1024, a potent PIM kinase inhibitor with promising antitumor efficacy and safety in models of AML
Researchers from Fudan University and affiliated organizations presented the discovery of novel PIM kinase inhibitors for the treatment of acute myeloid leukemia (AML). A literature-aided molecular ...
CAMBRIDGE, Mass., June 8, 2022 /PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food Drug and Administration (FDA ...
This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results